SCHRAMM VERN L has a total of 13 patent applications. Its first patent ever was published in 2004. It filed its patents most often in United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are TOLERO PHARMACEUTICALS INC, ASTRA ZENECA HOLDING FRANCE and SUMITOMO DAINIPPON PHARMA ONCOLOGY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 13 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Measurement | |
#5 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Schramm Vern L | 13 |
#2 | Tyler Peter Charles | 3 |
#3 | Evans Gary Brian | 3 |
#4 | Furneaux Richard Hubert | 2 |
#5 | Clinch Keith | 2 |
#6 | Hemeon Ivan | 1 |
#7 | Roday Setu | 1 |
#8 | Sauve Anthony A | 1 |
#9 | Mason Jennifer Mary | 1 |
#10 | Guha Chandan | 1 |
Publication | Filing date | Title |
---|---|---|
US2015210701A1 | Treatment of helicobacter pylori infections | |
US2013274220A1 | Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase | |
US2011201674A1 | Saporin-L1 inhibitors and uses thereof | |
US2010062995A1 | Transition state structure of human 5'methylthioadenosine phosphorylase | |
US2011053146A1 | Compounds and methods for detecting ricin and uses thereof | |
US2010222370A1 | Methods of treating cancer using inhibitors of 5′-methylthioadenosine phosphorylase | |
US2007275988A1 | Transition state structure and inhibitors of thymidine phosphorylases |